902494-31-9Relevant articles and documents
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Paragraph 0333, (2021/03/05)
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain
Han, Sangdon,Thoresen, Lars,Jung, Jae-Kyu,Zhu, Xiuwen,Thatte, Jayant,Solomon, Michelle,Gaidarov, Ibragim,Unett, David J.,Yoon, Woo Hyun,Barden, Jeremy,Sadeque, Abu,Usmani, Amin,Chen, Chuan,Semple, Graeme,Grottick, Andrew J.,Al-Shamma, Hussein,Christopher, Ronald,Jones, Robert M.
supporting information, p. 1309 - 1313 (2017/12/26)
The discovery of a novel, selective and fully efficacious CB2 agonist with satisfactory pharmacokinetic and pharmaceutical properties is described. Compound 6 was efficacious in a rat model of osteoarthritis pain following oral administration and, in contrast to morphine, maintained its analgesic effect throughout a 5-day subchronic treatment paradigm. These data were consistent with our hypothesis that full agonist efficacy is required for efficient internalization and recycling of the CB2 receptor to avoid tachyphylaxis. Based on its overall favorable preclinical profile, 6 (APD371) was selected for further development for the treatment of pain.
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
-
Page/Page column 130-131, (2011/02/24)
Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.